p-Guanidinobenzaldehyd | 28174-11-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-Guanidinobenzaldehyd
• 英文别名: 2-(4-Formylphenyl)guanidine
• CAS: 28174-11-0
• 化学式: C₈H₉N₃O
• 分子量: 163.179
• InChiKey: QWYMMOZEFSKGTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  亚磷酸三苯酯 、 氨基甲酸苄酯 、 p-Guanidinobenzaldehyd 在 溶剂黄146 作用下， 反应 2.0h， 生成 benzyl ((diphenoxyphosphoryl)(4-guanidinophenyl)methyl)carbamate
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Phosphonic Arginine Mimetics as Inhibitors of the M1 and M17 Aminopeptidases from Plasmodium falciparum

  摘要：

  The malaria parasite Plasmodium falciparum employs two metallo-aminopeptidases, PfA-M1 and PfA-M17, which are essential for parasite survival. Compounds that inhibit the activity of either enzyme represent leads for the development of new antimalarial drugs. Here we report the synthesis and structure-activity relationships of a small library of phosphonic acid arginine mimetics that probe the SI pocket of both enzymes and map the necessary interactions that would be important for a dual inhibitor.

  DOI：

  10.1021/jm4005972

文献信息

• COFERONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20120295874A1

  公开（公告）日：2012-11-22

  The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

  本发明涉及一种用于制备治疗性化合物的单体。该单体包括一个或多个可与目标分子结合的药效团，其解离常数小于300微摩尔，以及与药效团连接的连接元素。所述连接元素的分子量小于500道尔顿，通过直接连接或通过连接器间接与药效团相连。
• Phenylalanine derivative and proteinase inhibitor
  申请人：Okamoto, Shosuke

  公开号：EP0284632A1

  公开（公告）日：1988-10-05

  A phenylalanine derivative having the formula (I): wherein A represents (a) H2N-, (b) or B represents (a) (b) or wherein m is 0, 1, or 2 and n is 3, 4, or 5; X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) C1-C4 alkyloxy which may be substituted with (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) C1-C4 alkyl which may be substituted with halogen; Y represents or -OR3 wherein R1 and R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1-C4 alkylcarbonyl, (iii) C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2-Cs alkenyl which may be further substituted with hydroxycarbonyl or C1-C4 alkoxycarbonyl, (v) C1-C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C,-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl, (h) C1-C6 alkyl which may be substituted with C1-C4 alkoxy, C1-C4 alkoxycarbonyl, phenyl, or benzoyl, (i) CS-C7 cycloalkyl which may be substituted with C1-C4 alkoxycarbonyl or (j) R' and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1-C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1-C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1-C4 alkoxycarbonyl, or (iv) morpholyl; and R3 represents (a) hydrogen, (b) C1-C6 alkyl which may be substituted with (i) C1-C4 alkoxy, (ii) phenyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.

  具有以下式（I）的苯丙氨酸衍生物：其中A代表（a）H2N-，（b）或B代表（a）（b）或其中m为0、1或2，n为3、4或5；X代表（a）羟基，（b）硝基，（c）氨基，（d）苯氧基，其可以被（i）卤素或（ii）硝基取代，（e）C1-C4烷氧基，其可以被（i）苯基或（ii）苯甲酰基取代，（f）苯甲酰基，（g）吡啶氧基，其可以被（i）卤素或（ii）硝基取代，或（h）C1-C4烷基，其可以被卤素取代；Y代表或-OR3，其中R1和R2独立地为（a）氢，（b）苯基，其可以被（i）苯甲酰基，（ii）C1-C4烷基羰基，（iii）C1-C4烷基，其可以进一步被C1-C4烷氧羰基或羟基羰基取代，（iv）C2-Cs烯烃基，其可以进一步被羟基羰基或C1-C4烷氧羰基取代，（v）C1-C4烷氧羰基，或（vi）酰胺基，（c）吡啶基，其可以被卤素或羧基取代（d）咪唑基，（e）嘧啶基，（f）四唑基，（g）噻唑基，其可以被C1-C4烷基取代，其可以进一步被C1-C4烷氧羰基取代，（h）C1-C6烷基，其可以被C1-C4烷氧基，C1-C4烷氧羰基，苯基或苯甲酰基取代，（i）C5-C7环烷基，其可以被C1-C4烷氧羰基取代或（j）R'和R2可以与其连接的氮原子形成（i）哌嗪基，其可以在氮原子上被C1-C4烷基取代，其可以进一步被苯基取代，（ii）哌啶基，其可以被羧基或C1-C4烷氧羰基取代，（iii）吡咯基，其可以被C1-C4烷氧羰基取代，或（iv）吗啉基；R3代表（a）氢，（b）C1-C6烷基，其可以被（i）C1-C4烷氧基，（ii）苯基或（iii）吡啶基取代，或（c）吡啶；或其药学上可接受的酸盐。该苯丙氨酸衍生物作为蛋白酶具有有效性。
• [EN] ANTI-CANCER COMPOUNDS AND METHODS RELATED THERETO<br/>[FR] COMPOSES ANTICANCEREUX ET PROCEDES S'Y RAPPORTANT
  申请人：STEWART JOHN M

  公开号：WO2000011022A1

  公开（公告）日：2000-03-02

  The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula (I): [ACA]n-X wherein, X is a linker group having 2-5 functional groups or is absent, n = 1, and ACA is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V), and Formula (VI), as described herein. Other compounds described herein are defined by the Formula (VII), as described herein.

  本发明提供了一种有用的化合物，可用于抑制肿瘤生长和诱导细胞凋亡。一般来说，抗癌药物（ACA）由公式（I）描述：[ACA]n-X其中，X是具有2-5个功能基团的连接基团或不存在，n = 1，而ACA选自本文所述的公式（II），公式（III），公式（IV），公式（V）和公式（VI）的群组。本文还描述了其他化合物，其由公式（VII）所定义，如本文所述。
• Enzyme derivatives for use in the treatment of venous thrombosis, compositions containing them and their preparation
  申请人：BEECHAM GROUP PLC

  公开号：EP0009879A1

  公开（公告）日：1980-04-16

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier together with an in vivo fibrinolytic enzyme as defined herein wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range 10-6 sec-1 to 10-3sec-1 in isotonic aqueous media at pH 7.4 at 37°C; is useful in the treatment of venous thrombosis.

  一种药物组合物，它包括药学上可接受的载体和本文定义的体内纤维蛋白溶解酶，其中纤维蛋白溶解活性所必需的催化位点被一个基团阻断，该基团可通过水解去除，水解的假一阶速率常数在 10-6 秒-1 到 10-3 秒-1 之间，在 37°C pH 值为 7.4 的等渗水介质中；该药物组合物可用于治疗静脉血栓。
• Enzyme derivatives, and their preparation
  申请人：BEECHAM GROUP PLC

  公开号：EP0028489A1

  公开（公告）日：1981-05-13

  An enzyme derivative comprises a binary complex between streptokinase and plasminogen in which the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis such that the pseudo-first order rate constant for hydrolysis of the derivative is in the range 10-6sec-1to 10-3 sec-1 in isotonic aqueous media at pH 7.4 at 37°C, and is useful in the treatment of venous thrombosis.

  一种酶衍生物包括链激酶和纤溶酶原之间的二元复合物，其中对纤维蛋白溶解活性至关重要的催化位点被一个基团阻断，该基团可通过水解作用移除，因此在 37°C pH 值为 7.4 的等渗水介质中，该衍生物水解的假一阶速率常数在 10-6 秒-1 至 10-3 秒-1 之间，可用于治疗静脉血栓。